For the Inventor, By the Inventor

Enter assignee name

Burnaby, Canada

Xenon Pharmaceuticals Inc.

USPTO Granted Patents = 109

EPO Patents = 43

Trademarks = 3

Forward Citations = 747

Loading Chart...

Loading Chart...

148 inventors (with patents filed for the assignee):

Shaoyi Sun (46 out of 49 patents)

Sultan Chowdhury (43 out of 44 patents)

Jianmin Fu (32 out of 35 patents)

4. Rajender Kamboj (32 out of 34 patents)

5. Shifeng Liu (29 out of 30 patents)

6. Serguei Sviridov (27 out of 41 patents)

7. Thilo Focken (25 out of 25 patents)

8. Alla Yurevna Zenova (25 out of 25 patents)

9. Christoph Martin Dehnhardt (25 out of 51 patents)

10. Vishnumurthy Kodumuru (25 out of 28 patents)

11. Michael Edward Grimwood (23 out of 24 patents)

12. Qi Jia (23 out of 25 patents)

13. Zaihui Zhang (21 out of 50 patents)

14. Mikhail A Chafeev (20 out of 29 patents)

15. Nagasree Chakka (18 out of 21 patents)

Core Competencies:

Potassium Channel Modulator

Selective Sodium Channel Activators

Heteroaryl-Substituted Sulfonamides

Therapeutic Agents

Substituted Benzamides

Spiro-Oxindole Compounds

Anhedonia Treatment

Bioavailability Enhancement

Analgesic Agents

Pyridine Derivatives

Benzenesulfonamide Compounds

Synthetic Methods

109 patents: Sort by Forward Citations

1. 12319657 - Solid state crystalline forms of a selective potassium channel modulator (2025-06-03),

2. 12178811 - Methods of treating depressive disorders (2024-12-31),

3. 12171759 - Methods and uses for treating anhedonia (2024-12-24),

4. 12054486 - Pyridine derivatives and their use as sodium channel activators (2024-08-06),

5. 11957675 - Methods and uses for treating anhedonia (2024-04-16),

6. 11639351 - Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents (2023-05-02),

7. 11325902 - Benzenesulfonamide compounds and their use as therapeutic agents (2022-05-10),

8. 11299490 - Benzenesulfonamide compounds and their use as therapeutic agents (2022-04-12),

9. 11203572 - Substituted benzamides and methods of use thereof (2021-12-21),

10. 11174268 - Benzenesulfonamide compouds and their use as therapeutic agents (2021-11-16),

11. 11149002 - Therapeutic compounds and methods of use thereof (2021-10-19),

12. 11135214 - Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel opener (2021-10-05),

13. 11130726 - Therapeutic compounds and methods of use thereof (2021-09-28),

14. 11091441 - Solid state crystalline forms of a selective potassium channel modulator (2021-08-17),

15. 10981905 - Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents (2021-04-20),

Xenon Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering and developing innovative therapeutics. With a strong commitment to precision medicine, Xenon utilizes its proprietary platform to identify and validate novel targets in genetically and clinically defined patient populations. The company's goal is to improve the lives of patients living with neurological disorders. For more information, please visit their official website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

109 Patents

#4 in Burnaby

#110 in Canada

#7,012 in the World

Burnaby, Canada

Xenon Pharmaceuticals Inc.

Forward Citations = 747

148 inventors:

Shaoyi Sun (46 out of 49 patents)

Sultan Chowdhury (43 out of 44 patents)

Jianmin Fu (32 out of 35 patents)

4. Rajender Kamboj (32 out of 34 patents)

5. Shifeng Liu (29 out of 30 patents)

Please report any incorrect information to support@idiyas.com

Loading…